Decoy Therapeutics announced that its next-generation Designable Multi-Antivirals (D-MAVs™) demonstrated potent in vitro activity against Ebola Zaire and Marburg viruses, surpassing existing treatments like remdesivir. The company is pursuing expedited FDA approval via the Animal Rule pathway, which allows faster regulatory review based on animal studies, targeting biodefense applications. Decoy aims to develop a broad-spectrum pan-filovirus antiviral for pre- and post-exposure protection, with potential weekly dosing and eligibility for a lucrative FDA Priority Review Voucher. This strategy could bring non-dilutive government funding and commercial value while addressing urgent viral threats with high mortality rates.
Decoy Therapeutics' pan-filovirus program is the subject, with Pluang's health sector data providing context. As of Sep 22, 2026 18:11 WIB, among 95 priced US health stocks on Pluang, 50 rose and 38 fell. GSK traded at USD 50.50 with a 1-day decline of 1.14% and a typical hold time of 91 days, contrasting with BioNano Genomics Inc (BNGO) at USD 1.85, which gained 1.09% and has a shorter hold time of 49 days. Cassava Sciences Inc (FLNA) was priced at USD 0.73, down 1.04%, with a typical hold time of 39 days, showing varied investor activity and order splits across these stocks.
Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...
HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...
Smiths Group reported solid fiscal 2026 results, meeting EPS and revenue expectations with an EPS of $0.66 and revenue of $1.37 billion. The company improved operating profit, driven by strategic portfolio changes including selling non-core divisions...
Cintas Corporation is set to report its Q3 earnings with an expected EPS of $1.35 and revenue of $2.98 billion, up from $2.72 billion last year. The growth is supported by strong customer retention, increased demand for services like AED Rentals, and...
An analyst from Barclays has lowered Constellation Brands' stock price target to $122, slightly above its current trading price near a 52-week low. The company is refining its beer portfolio strategy with brand-specific plans and supply-chain improve...
